Aug. 7, 2000 (Washington) -- The popular weight-loss herb ephedra has been under fire lately, with claims that it can have dangerous side effects. But now a panel of experts who conducted an industry-financed review may turn down the heat, saying the herb, also known as ma huang, does not cause serious heart-related side effects when used as directed.
This conclusion has now set the stage for a two-day public meeting sponsored by the Department of Health and Human Services (HHS), scheduled to begin Tuesday, regarding how ephedra-containing products should be regulated.
Drawing their conclusions from a review of about 1,200 side effects reported to the FDA, the seven-member panel said Monday that conservative estimates show that there is no greater risk of heart-related side effects occurring in ephedra users than in the population at large.
Based upon those same reports, the FDA in April proposed a rule that would ban the combination of ephedra with stimulants such as caffeine, and would require a warning label to outline and highlight potential side effects, such as heart attacks, strokes, and seizures.
Proponents of the dietary supplement believe the FDA rule is unmerited, and if passed, could in effect act as a ban on ephedra containing products, of which more than half contain caffeine. They now plan to use this latest review, paid for by the industry group American Herbal Products Association (AHPA), to criticize the FDA proposal at the two-day meeting.
Theodore Farber, PhD, DABT, a poisons expert and member of the panel, tells WebMD that the pure number of adverse events associated with ephedra might suggest a cause-and-effect relationship, but that doesn't hold up upon review by the multidisciplinary panel and when compared to the usual incidence of heart-related events in the general population. Farber is a past office director of the FDA
Advocates for ephedra already have won the first round of this ongoing bout with the federal agency. In June 1997, the FDA proposed a rule that would have banned the marketing of ephedra for weight loss and weight management. But the FDA was forced to abandon that rule, thanks in large part to a Government Accounting Office (GAO) report that found no basis for the agency's recommendations.